Budget Impact on the Use of Pegfilgrastim to Reduce the Febrile Neutropenia During Chemotherapy for Breast Cancer with Moderate Risk Compared to a Standard Therapy

MLA

Yong Joo Lee, et al. “Budget Impact on the Use of Pegfilgrastim to Reduce the Febrile Neutropenia During Chemotherapy for Breast Cancer with Moderate Risk Compared to a Standard Therapy.” Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 17, no. 7, May 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....41c220b1ed0b1f8bbdecf6ddcca9da1f&authtype=sso&custid=ns315887.

APA

Yong Joo Lee, Sang Yhun Ju, C.M. Kim, S.B. Heo, & W.S. Choi. (2016). Budget Impact on the Use of Pegfilgrastim to Reduce the Febrile Neutropenia During Chemotherapy for Breast Cancer with Moderate Risk Compared to a Standard Therapy. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7).

Chicago

Yong Joo Lee, Sang Yhun Ju, C.M. Kim, S.B. Heo, and W.S. Choi. 2016. “Budget Impact on the Use of Pegfilgrastim to Reduce the Febrile Neutropenia During Chemotherapy for Breast Cancer with Moderate Risk Compared to a Standard Therapy.” Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research 17 (7). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....41c220b1ed0b1f8bbdecf6ddcca9da1f&authtype=sso&custid=ns315887.